维生素D预防胸骨切开愈合并发症:REINFORCE-D试验
REINFORCE-D是一项单中心、随机、双盲、安慰剂对照临床试验,计划纳入600例接受正中胸骨切开心脏手术的患者,比较胆钙化醇与安慰剂对术后胸骨愈合并发症发生率的影响。根据血清钙二醇水平分组并据此给药的试验设计属首次,旨在探索维生素D在术后愈合问题中的潜在作用。
要点
- 血清钙二醇低于80 nmol/L与钙吸收受损及骨丢失风险相关,被视为胸骨愈合的危险因素。
- 主要终点为术后所有胸骨愈合并发症的发生率,次要终点包括骨愈合分级、住院和ICU天数等。
- 试验计划纳入18至95岁接受正中胸骨切开心脏手术的患者,分安慰剂组和治疗组各约300例。
核心结论
- REINFORCE-D是首个依据血清钙二醇水平分组并据此给药的试验,旨在比较胆钙化醇与安慰剂对胸骨愈合并发症的影响。
研究设计与样本
- 单中心、随机、双盲、安慰剂对照临床试验,计划纳入600例患者(安慰剂组约300例,治疗组约300例),历时4年。
- 纳入18至95岁、符合正中胸骨切开心脏手术指征的男性和女性患者。
主要发现
- 正中胸骨切开并发症发生率为0.5%至5%,并发症相关死亡率变化范围为7%至80%。
- 血清钙二醇浓度低于80 nmol/L导致钙吸收受损并伴随骨丢失风险,被视为胸骨愈合过程的危险因素。
关键数值与推荐
- 血清钙二醇浓度低于80 nmol/L被认定为钙吸收受损和骨丢失风险相关的阈值。
- 主要终点为比较胆钙化醇组与安慰剂组术后所有胸骨愈合并发症的发生率。
- 次要终点包括试验结束时胸骨骨愈合分级、住院时长、ICU天数、机械通气天数及因胸骨并发症再入院次数。
临床怎么用
- 对于接受正中胸骨切开心脏手术的患者,可关注血清钙二醇水平作为胸骨愈合风险的评估指标。
局限性
- 原文未明确报告研究的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Most cardiac surgery patients undergo median sternotomy during open heart surgery. Sternotomy healing is an arduous, very complex, and multifactorial process dependent on many independent factors affecting the sternum and the surrounding soft tissues. Complication rates for median sternotomy range from 0.5 to 5%; however, mortality rates from complications are very variable at 7-80%. Low calcidiol concentration below 80 nmol/L results in calcium absorptive impairment and carries a risk of bone loss, which is considered as a risk factor in the sternotomy healing process. The primary objective of this clinical trial is to compare the incidence of all postoperative sternotomy healing complications in two parallel patient groups administered cholecalciferol or placebo. The secondary objectives are focused on general patient recovery process: sternal bone healing grade at the end of the trial, length of hospitalization, number of days spent in the ICU, number of days spent on mechanical lung ventilation, and number of hospital readmissions for sternotomy complications. METHODS: This clinical trial is conducted as monocentric, randomized, double-blind, placebo-controlled, with planned enrollment of 600 patients over 4 years, approximately 300 in the placebo arm and 300 in the treatment arm. Males and females from 18 to 95 years of age who fulfill the indication criteria for undergoing cardiac surgery with median sternotomy can be included in this clinical trial, if they meet the eligibility criteria. DISCUSSION: REINFORCE-D is the first monocentric trial dividing patients into groups based on serum calcidiol levels, and with dosing based on serum calcidiol levels. This trial may help to open up a wider range of postoperative healing issues. TRIAL REGISTRATION: EU Clinical Trials Register, EUDRA CT No: 2016-002606-39 . Registered on September 8, 2016.
引用
- Čečrle M, Černý D, Sedláčková E, et al. Vitamin D for prevention of sternotomy healing complications: REINFORCE-D trial. Trials. 2020. PMID: 33308291. doi:10.1186/s13063-020-04920-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。